Sepracor’s Great Value Recognized by Japan’s Dainippon Sumitomo

Sepracor (NASDAQ:SEPR) shares surged up to 30% higher in early afternoon trading as news broke from the Nikkei of an approximately $2.71 billion offer from Dainippon Sumitomo. Sepracor’s stock has been hammered over the last few years, and recently there have been some disappointing clinical trial results. We wrote about one of these disappointing trials in early July (Study of Sepracor’s Depression Drug Has Investors Gloomy), on that day the stock was down nearly 20% after two trials had been less than impressive. However, at that time we reiterated that this stock was simply too cheap, selling for just a 6.5x multiple of the most conservative analyst estimate.

Since we first wrote about Sepracor, analysts have become more positive on Sepracor’s ability to increase earnings. Even though the price had come up somewhat since July, the stock was still selling for a lowly 6.5x the lowest analyst estimate for full year earnings. We had upgraded SEPR to Greatly Undervalued from just Undervalued. So, we were not surprised to see that Dainippon Sumitomo had seen an opportunity in Sepracor and their steady stream of revenue from Lunesta.

There is more than just valuation that appealed to Dainippon in this deal. They are anxious to add to their pipeline of central nervous system drugs and Sepracor does have some exciting potential in the drugs currently in clinical trials. Furthermore, Dainippon has an eye towards the established U.S. sales force of Sepracor, which is more than 1,000 strong. The Japanese drug maker is seeking approval from the FDA for its lurasidone schizophrenia treatment, making its first major effort in the U.S. market. If it is approved, sales of lurasidone should begin by 2011 and the drug has the potential to be a blockbuster.

Drug maker stocks can be volatile, as the results of trials often lead to huge swings in the stock’s price. However, Sepracor was one drug stock that we through meet our criteria for a great value stock with potential for appreciation. It was selling very cheaply and has been exceeding expectations for sales and earnings over the last two quarters. In addition, it still has a steady stream of revenue coming from Lunesta, in addition to having great potential in their pipeline. We are not surprised that Dainippon would bid for this company, and it seems to pave the way for a push into the U.S. market.

Sepracor’s Great Value Recognized By Japan’s Dainippon Sumitomo

About Ockham Research 645 Articles

Ockham Research is an independent equity research provider based in Atlanta, Georgia. Security analysis at Ockham Research is based upon the principle known as Ockham's Razor, named for the 14th- century Franciscan friar, William of Ockham. The principle states that a useful theory should utilize as few elements as possible, because efficiency is valuable. In this spirit, our goal is to make the investing environment as simple and understandable as possible, yet no simpler than is necessary.

We utilize this straightforward approach to value over 5500 securities, with key emphasis given to the study of individual securities' price-to-sales, price-to-cash earnings and other historical valuation ranges. Our long term value investing methodology is powered by the teachings of Ben Graham and it has proven to be very adept at identifying stock prices that are out of line with fundamental factors.

Ockham Research provides its research in a variety of forms and products including our company specific reports, portfolio analytics tools, newsletters, and blog posts. We also offer a white labeling research solution that can give any financial services firm their own research presence without the time and cost associated with building such a robust coverage universe of their own.

Be the first to comment

Leave a Reply

Your email address will not be published.